NeoGenomics logo
NeoGenomics NEO
$ 12.07 1.81%

Quarterly report 2025-Q2
added 07-29-2025

report update icon

NeoGenomics Income Statement 2011-2025 | NEO

Annual Income Statement NeoGenomics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.53 B 1.84 B 1.96 B 2.57 B 5.53 B 3.33 B 1.42 B 616 M 627 M 413 M 216 M 208 M 128 M 75.3 M

Shares

127 M 126 M 124 M 120 M 109 M 100 M 85.6 M 79.4 M 77.5 M 60.5 M 53.5 M 48.3 M 45 M 42.8 M

Historical Prices

12.1 14.7 15.8 21.4 51 28.3 19.6 8.4 8.07 6.37 4.54 3.58 3.34 1.67

Net Income

-78.7 M -88 M -144 M -8.35 M 4.17 M 8.01 M 2.64 M -846 K -5.72 M -2.54 M 1.13 M 2.03 M 65 K -1.18 M

Revenue

661 M 592 M 510 M 484 M 444 M 409 M 277 M 259 M 244 M 99.8 M 87.1 M 66.5 M 59.9 M 43.5 M

Cost of Revenue

370 M 347 M 322 M 297 M 259 M 212 M 149 M 138 M 134 M - - - - -

Gross Profit

290 M 245 M 188 M 187 M 186 M 197 M 127 M 120 M 110 M 43.8 M 40.7 M 31.7 M 26.8 M 19.4 M

Operating Income

-92.1 M -108 M -158 M -119 M -14 M 13 M 10 M 2.9 M 2.16 M -5.64 M 2.22 M 3.17 M 1.21 M -409 K

Interest Expense

-379 K 644 K -213 K 8.22 M 7.02 M 3.71 M 6.23 M 5.54 M - 854 K 985 K 989 K 1.15 M 768 K

EBITDA

-53 M -70.3 M -122 M -88.6 M 11.9 M 43.3 M 31.8 M 26 M 29.2 M 1.51 M 7.86 M 7.59 M 5.03 M 1.68 M

Operating Expenses

382 M 352 M 346 M 306 M 200 M 184 M 117 M 117 M 104 M 49.4 M 38.5 M 28.6 M 25.6 M 19.8 M

General and Administrative Expenses

260 M 243 M 243 M 221 M 144 M 128 M 84.8 M 88.8 M 75.8 M 33.6 M 23.8 M 17.4 M 15.8 M 12.9 M

All numbers in USD currency

Quarterly Income Statement NeoGenomics

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

128 M 127 M 128 M 127 M 126 M 126 M 127 M 126 M 125 M 125 M 127 M 124 M 124 M 124 M 124 M 123 M 118 M 116 M 112 M 110 M 108 M 104 M 104 M 104 M 98.3 M 94.7 M 93.3 M 87.3 M 81 M 80.5 M 86.7 M 79.6 M 79.4 M 78.6 M 78.5 M 78.1 M 77.4 M 76.1 M 60.9 M 60.5 M 60.4 M 60.3 M 60 M 54.4 M 49.9 M 49.3 M 49 M 48.9 M 48.8 M 46.3 M 45.3 M 45.2 M 45 M 44.7 M 43.1 M 43.1 M 42.9 M 41.7 M

Net Income

-45.1 M -25.9 M - -17.7 M -18.6 M -27.1 M - -18.5 M -24.3 M -30.8 M - -36.9 M -35.3 M -49.4 M - -20.3 M 75.9 M -22.1 M - 2.56 M -6.82 M -6.98 M 6.3 M 2.14 M 1.99 M -2.42 M 353 K 2.02 M -380 K 644 K 4.55 M -4.26 M 483 K -1.16 M -6.22 M -67 K 413 K 155 K -1.47 M -125 K -176 K -761 K 1.05 M -291 K 274 K 102 K 857 K 900 K 273 K 3 K -114 K -975 K 551 K 603 K 152 K -143 K -293 K -893 K

Revenue

181 M 168 M - 168 M 165 M 156 M - 152 M 147 M 137 M - 129 M 125 M 117 M - 121 M 122 M 116 M - 125 M 87 M 106 M 107 M 105 M 102 M 95.6 M 76.5 M 69.1 M 67.7 M 63.4 M 61.4 M 59.1 M 62.3 M 57.4 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

104 M 94.8 M - 92.9 M 92 M 90.8 M - 89.6 M 87 M 82.4 M - 79.9 M 81.1 M 78.9 M - 74.1 M 68.7 M 74 M - 71.4 M 59 M 59.7 M - 53.8 M 52.7 M 48.5 M - 36.8 M 37.2 M 36.1 M - 34.2 M 34.9 M 34.5 M - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

77.3 M 73.2 M - 74.9 M 72.5 M 65.5 M - 62.3 M 59.9 M 54.8 M - 48.9 M 43.9 M 38.2 M - 47.2 M 53 M 41.6 M - 54.1 M 28 M 46.4 M 49.9 M 50.8 M 49 M 47.1 M 37.1 M 32.3 M 30.5 M 27.3 M 26.8 M 24.9 M 27.4 M 22.9 M 27.3 M 27.3 M 28.6 M 27.2 M 12.2 M 11.2 M 10.8 M 9.54 M 11.5 M 10.3 M 10.2 M 8.71 M 9.16 M 8.17 M 7.16 M 7.25 M 6.43 M 5.89 M 7.37 M 7.14 M 5.83 M 5.07 M 4.66 M 3.86 M

Operating Income

-47.6 M -27.8 M - -21.2 M -21.9 M -30.6 M - -24.2 M -29.9 M -35.1 M - -39.5 M -39.7 M -52 M - -39.7 M -22.4 M -15.1 M - 4.67 M -18.9 M -5.29 M - 3.66 M 4.48 M 2.55 M - 3.92 M 794 K 2.5 M - -2.06 M 1.84 M -580 K - 1.4 M 2.19 M 1.92 M - 114 K 28 K -561 K - -73 K 578 K 394 K - 1.16 M 505 K 305 K - -684 K 839 K 861 K - 42 K -114 K -711 K

Interest Expense

482 K 65 K - 317 K -2 K -263 K - -96 K 730 K 1.76 M - 139 K 926 K 168 K - 1.3 M 902 K 1.18 M - 2.46 M 1.55 M 819 K - 203 K 1.3 M 1.83 M - 1.87 M 1.41 M 1.49 M - - -1.41 M -1.36 M - -1.47 M -1.45 M -1.59 M - -239 K -189 K 195 K - - - 265 K - 231 K 232 K 285 K - 291 K 288 K 258 K - 185 K 179 K 182 K

EBITDA

-39.5 M -18.5 M - -12.8 M -13.6 M -20.7 M - -15.4 M -21.1 M -26 M - -31 M -31.2 M -43.6 M - -17.9 M -8.74 M -8.43 M - 23.4 M -6.73 M 947 K - 18.9 M 14.8 M 7.82 M - 15.4 M 8.24 M 6.14 M - 9.68 M 9.75 M 3.4 M - 12.9 M 9.52 M 5.51 M - 5.08 M 3.28 M 1.02 M - 3.86 M 2.98 M 1.54 M - 4.28 M 2.56 M 1.3 M - 1.86 M 2.44 M 1.61 M - 1.53 M 849 K -223 K

Operating Expenses

125 M 101 M - 96.1 M 94.4 M 96 M - 86.5 M 89.8 M 89.9 M - 88.4 M 83.6 M 90.3 M - 87 M 75.4 M 56.7 M - 49.4 M 46.9 M 51.7 M - 47.2 M 44.5 M 44.6 M - 28.4 M 29.7 M 24.8 M - 27 M 25.5 M 23.5 M - 26 M 26.4 M 25.3 M - 11.1 M 10.8 M 10.1 M - 10.4 M 9.66 M 8.32 M - 7.01 M 6.65 M 6.94 M - 6.58 M 6.53 M 6.28 M - 5.03 M 4.77 M 4.58 M

General and Administrative Expenses

71.7 M 68.2 M - 67 M 63.3 M 65.8 M - 61.5 M 60.3 M 61.5 M - 64.3 M 58 M 66.2 M - 63.8 M 54.6 M 40.5 M - 36.1 M 34.6 M 36.3 M - 33.1 M 29.6 M 32.1 M - 21.1 M 21 M 17.1 M - 18.3 M 18.4 M 17 M - 19 M 18.8 M 18 M - 7.44 M 7.08 M 6.52 M - 6.37 M 5.87 M 5.05 M - 4.34 M 4.06 M 4.18 M - 3.93 M 4.07 M 3.75 M - 3.18 M 2.91 M 2.7 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company NeoGenomics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 16.75 -1.28 % $ 99.4 M israelIsrael
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.9 7.3 % $ 183 M chinaChina
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 1.57 -3.08 % $ 2 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Castle Biosciences Castle Biosciences
CSTL
$ 38.44 -0.5 % $ 1.07 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 12.0 0.93 % $ 340 M israelIsrael
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
DexCom DexCom
DXCM
$ 66.39 -0.85 % $ 25.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 226.5 - $ 166 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
$ 101.57 0.07 % $ 18.8 B usaUSA
Fulgent Genetics Fulgent Genetics
FLGT
$ 26.81 -1.22 % $ 811 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 19.74 -3.99 % $ 1.06 B usaUSA
Celcuity Celcuity
CELC
$ 102.0 -3.09 % $ 4.02 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.53 -1.4 % $ 113 K usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 0.31 -9.4 % $ 9.1 M usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 28.81 0.03 % $ 1.21 B usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 222.3 0.04 % $ 40.3 B usaUSA
Guardant Health Guardant Health
GH
$ 103.47 1.37 % $ 12.7 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Illumina Illumina
ILMN
$ 133.88 -0.73 % $ 21.3 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 196.14 1.64 % $ 10.1 B usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 183.36 0.47 % $ 20.4 B usaUSA
Biodesix Biodesix
BDSX
$ 7.56 -3.63 % $ 980 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 410.24 1.17 % $ 29.9 B schweizSchweiz
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 262.29 -0.71 % $ 22 B usaUSA
Myriad Genetics Myriad Genetics
MYGN
$ 7.01 -2.84 % $ 635 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 183.39 -1.71 % $ 15.1 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
$ 701.16 -0.43 % $ 57.8 B usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 67.34 1.08 % $ 4.66 B usaUSA
Neogen Corporation Neogen Corporation
NEOG
$ 6.8 -0.95 % $ 1.47 B usaUSA
Agilent Technologies Agilent Technologies
A
$ 140.63 0.69 % $ 42.8 B usaUSA
Biomerica Biomerica
BMRA
$ 2.56 0.29 % $ 5.88 M usaUSA
Bioventus Bioventus
BVS
$ 7.59 0.53 % $ 475 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael